[HTML][HTML] Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphisms and risk of venous thromboembolism–a meta-analysis and systematic review

Q Zhang, YR Jin, XM Li, XQ Peng, N Peng, JF Song… - Vasa, 2020 - econtent.hogrefe.com
Background: A 4G/5G polymorphism in the promoter region of the plasminogen activator
inhibitor type 1 (PAI-1) gene has been reported to enhance the plasma levels of PAI-1 …

Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase …

B Simone, V De Stefano, E Leoncini, J Zacho… - European journal of …, 2013 - Springer
Genetic and environmental factors interact in determining the risk of venous
thromboembolism (VTE). The risk associated with the polymorphic variants G1691A of factor …

[HTML][HTML] Epidemiology of activated protein C resistance and factor v leiden mutation in the mediterranean region

MM Jadaon - Mediterranean journal of hematology and infectious …, 2011 - ncbi.nlm.nih.gov
Venous thromboembolic disorders (VTE) are serious disorders with high morbidity and
mortality rates. Many genetic and acquired risk factors were identified to cause VTE. The …

Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and risk of venous thromboembolism: a meta-analysis

J Wang, C Wang, N Chen, C Shu, Y He, Y Zhou - Thrombosis research, 2014 - Elsevier
Introduction The plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism was
considered to be associated with risk of venous thromboembolism (VTE), while evidence …

Genetic mutations in Turkish population with pulmonary embolism and deep venous thrombosis

E Kupeli, H Verdi, A Simsek, FB Atac… - Clinical and Applied …, 2011 - journals.sagepub.com
Venous thromboembolism (VTE) is a universal health hazard. Inherited and acquired risk
factors increase the risk of VTE. We evaluated the relationship between factor V (G1691A …

[HTML][HTML] Psoriatic inflammation-induced atypically located venous thromboembolism: A case of immuno-thrombosis

AT Güven, YZ Şener, M Özdede - Nigerian Journal of Clinical …, 2023 - journals.lww.com
The immune and hemostatic systems share a common evolutionary origin, both defend
against threats to organisms, and inflammation can cause venous thromboembolism. We …

[HTML][HTML] Dual diverse dynamic reversible actions of Ankaferd on EPCR and PAI-1 inside vascular endothelial cells with and without LPS

A Karabıyık, E Yılmaz, Ş Güleç, İ Haznedaroğlu, N Akar - 2012 - jag.journalagent.com
OBJECTIVE: Ankaferd Blood Stopper (ABS) comprises a mixture of the plants Thymus
vulgaris, Glycyrrhiza glabra, Vitis vinifera, Alpinia officinarum ve Urtica dioica. ABS has been …

The role of factor V Leiden in adult patients with venous thromboembolism: a meta-analysis of published studies from Turkey

A Eroglu, D Sertkaya, N Akar - Clinical and Applied …, 2012 - journals.sagepub.com
Factor V Leiden (FVL) is the most common inherited risk factor for venous thromboembolism
(VTE). The frequency of FVL in patients with VTE has been reported from different parts of …

Failure to lyse venous thrombi because of elevated plasminogen activator inhibitor 1 (PAI-1) and 4G polymorphism of its promotor genome (The PAI-1/4G syndrome)

MM Bern, N McCarthy - Clinical and Applied Thrombosis …, 2010 - journals.sagepub.com
Plasminogen activator Inhibitor 1 (PAI-1) inhibits plasminogen activators leading to
decreased fibrinolysis and increased risk of thromboembolic disease (TED). Shifts in PAI-1 …

[PDF][PDF] BHMT polymorphism and susceptibility to PTE in Chinese patients

WH Zhang, SM Zhao, JF Guo, YP Liu… - Eur Rev Med …, 2023 - europeanreview.org
OBJECTIVE: Pulmonary thromboembolism (PTE) is as a common form of venous thrombosis
and a potentially fatal cardiovascular disorder, which has become a severe clinical problem …